Metsera

United States - New York

• 14/11/2024
• Series B
• $215,000,000

Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised $290 million in financing from leading healthcare investors and is based in New York City.

Related People

Whit BernardFounder

United States - Brooklyn, New York

As a Managing Partner at Population Health Partners (PHP), I work alongside a team of innovators, strategists, and veteran drug developers to build important new companies and advance new technologies with the potential for transformative impact in highly prevalent diseases.

Prior to co-founding PHP, I led Business Development for The Medicines Company, a role which culminated in the sale of the company to Novartis for $9.7Bn in early 2020. Before MDCO I spent several years in McKinsey & Company's Pharmaceuticals and Medical Products practice, where I specialized in portfolio and corporate strategy for early-stage biotechs, as well as commercial strategy for Top 20 pharmacos.

Before McKinsey I worked in the arts, as a Fulbright Scholar in Latvia and then Director of Development at the International Contemporary Ensemble.

LinkedIn https://www.linkedin.com/in/whitbernard/